IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences (NASDAQ: IDYA), a precision medicine oncology company, announced the granting of inducement stock options to a new employee. The Compensation Committee approved non-qualified stock options to purchase 95,600 shares of common stock under the company's 2023 Employment Inducement Incentive Award Plan.
The stock options were granted at an exercise price of $22.29 per share, matching IDEAYA's closing price on the grant date. The options have a 10-year term and will vest over four years, with 25% vesting after the first year and the remaining 75% vesting monthly over the following three years, subject to continued employment.
IDEAYA Biosciences (NASDAQ: IDYA), un'azienda di oncologia di medicina di precisione, ha annunciato la concessione di opzioni azionarie di incentivo a un nuovo dipendente. Il Comitato per la Compensazione ha approvato opzioni azionarie non qualificate per l'acquisto di 95.600 azioni ordinarie nell'ambito del Piano di Incentivi per l'Assunzione 2023 dell'azienda.
Le opzioni azionarie sono state concesse a un prezzo di esercizio di 22,29 $ per azione, corrispondente al prezzo di chiusura di IDEAYA alla data di concessione. Le opzioni hanno una durata di 10 anni e maturano in quattro anni, con il 25% che matura dopo il primo anno e il restante 75% che matura mensilmente nei successivi tre anni, subordinatamente alla permanenza in servizio.
IDEAYA Biosciences (NASDAQ: IDYA), una empresa de oncología de medicina de precisión, anunció la concesión de opciones sobre acciones de incentivo a un nuevo empleado. El Comité de Compensación aprobó opciones sobre acciones no calificadas para comprar 95,600 acciones comunes bajo el Plan de Incentivos para la Contratación 2023 de la compañía.
Las opciones sobre acciones se otorgaron a un precio de ejercicio de $22.29 por acción, igualando el precio de cierre de IDEAYA en la fecha de concesión. Las opciones tienen un plazo de 10 años y se consolidarán durante cuatro años, con un 25% consolidado después del primer año y el 75% restante consolidándose mensualmente durante los siguientes tres años, sujeto a la continuidad en el empleo.
IDEAYA Biosciences (NASDAQ: IDYA)는 정밀 의학 암 치료 회사로, 신입 직원에게 유인 주식 옵션을 부여했다고 발표했습니다. 보상 위원회는 회사의 2023년 고용 유인 인센티브 상 계획에 따라 95,600주의 보통주를 구매할 수 있는 비자격 주식 옵션을 승인했습니다.
주식 옵션은 부여일 IDEAYA 종가와 동일한 주당 22.29달러의 행사 가격으로 부여되었습니다. 옵션의 유효 기간은 10년이며, 4년에 걸쳐 권리가 발생하며, 첫 해에 25%가 발생하고 나머지 75%는 이후 3년 동안 매월 발생하며, 계속 고용 상태를 유지해야 합니다.
IDEAYA Biosciences (NASDAQ : IDYA), une entreprise d'oncologie en médecine de précision, a annoncé l'octroi d'options d'achat d'actions incitatives à un nouvel employé. Le comité de rémunération a approuvé des options d'achat d'actions non qualifiées pour l'achat de 95 600 actions ordinaires dans le cadre du plan d'incitation à l'emploi 2023 de la société.
Les options d'achat d'actions ont été accordées à un prix d'exercice de 22,29 $ par action, correspondant au cours de clôture d'IDEAYA à la date d'attribution. Les options ont une durée de 10 ans et seront acquises sur une période de quatre ans, avec 25 % acquis après la première année et les 75 % restants acquis mensuellement sur les trois années suivantes, sous réserve de la poursuite de l'emploi.
IDEAYA Biosciences (NASDAQ: IDYA), ein Unternehmen für Präzisionsmedizin in der Onkologie, gab die Gewährung von Anreizaktienoptionen an einen neuen Mitarbeiter bekannt. Der Vergütungsausschuss genehmigte nicht qualifizierte Aktienoptionen zum Kauf von 95.600 Aktien des Stammkapitals im Rahmen des Beschäftigungsanreizplans 2023 des Unternehmens.
Die Aktienoptionen wurden zu einem Ausübungspreis von 22,29 $ pro Aktie gewährt, entsprechend dem Schlusskurs von IDEAYA am Gewährungstag. Die Optionen haben eine Laufzeit von 10 Jahren und werden über vier Jahre unverfallbar, wobei 25 % nach dem ersten Jahr und die restlichen 75 % monatlich über die folgenden drei Jahre unverfallbar werden, vorbehaltlich der fortgesetzten Beschäftigung.
- None.
- None.
The 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of IDEAYA, or following a bona fide period of non-employment, as an inducement material to such individuals' entering into employment with IDEAYA, pursuant to Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets.
Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer
investor@ideayabio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302492990.html
SOURCE IDEAYA Biosciences, Inc.
FAQ
What stock options did IDEAYA Biosciences (IDYA) grant to its new employee?
What is the vesting schedule for IDEAYA's (IDYA) inducement stock options?
What is the purpose of IDEAYA's (IDYA) 2023 Inducement Plan?
How long is the term of IDEAYA's (IDYA) inducement stock options?
